KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Non Operating Income: 2010-2025

Historic Non Operating Income for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -$3.3 million.

  • Nektar Therapeutics' Non Operating Income fell 23.90% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.7 million, marking a year-over-year decrease of 2.89%. This contributed to the annual value of -$14.0 million for FY2024, which is 11.37% down from last year.
  • As of Q3 2025, Nektar Therapeutics' Non Operating Income stood at -$3.3 million, which was down 5.81% from -$3.2 million recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Non Operating Income ranged from a high of $26.3 million in Q1 2022 and a low of -$32.7 million during Q4 2021.
  • Moreover, its 3-year median value for Non Operating Income was -$2.5 million (2024), whereas its average is -$3.1 million.
  • Per our database at Business Quant, Nektar Therapeutics' Non Operating Income skyrocketed by 295.01% in 2022 and then plummeted by 445.52% in 2024.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Non Operating Income stood at -$32.7 million in 2021, then skyrocketed by 87.55% to -$4.1 million in 2022, then slumped by 110.97% to -$8.6 million in 2023, then climbed by 14.55% to -$7.3 million in 2024, then decreased by 23.90% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, -$3.2 million for Q2 2025, and -$1.8 million during Q1 2025.